— Know what they know.
Not Investment Advice

LAURUSLABS.BO

Laurus Labs Limited
1W: +5.8% 1M: +0.5% 3M: +3.6% YTD: +6.1% 1Y: +67.8% 3Y: +202.4% 5Y: +183.9%
₹1,024.55 ($10.87)
+32.00 (+3.22%)
 
BSE · Healthcare · Drug Manufacturers - Specialty & Generic · ₹553.1B · Alpha Radar Neutral · Power 44
Smart Money Score
Watch 25
Insider
Congress
ETF Holdings
Key Statistics
Market Cap₹553.1B ($5.9B)
52W Range517.05-1140.9
Volume35,210
Avg Volume92,555
Beta0.28
Dividend₹1.60
Analyst Ratings
No analyst coverage
Company Info
CEOSatyanarayana Chava
Employees6,007
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2016-12-19
Serene Chambers
Hyderabad 500034
IN
91 40 3980 4333
About Laurus Labs Limited

Laurus Labs Limited, together with its subsidiaries, engages in the development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company develops, manufactures, and sells APIs and advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C therapeutic areas. It also develops and manufactures oral solid formulations for ARVs, anti-diabetic, cardiovascular, PPIs, and central nervous system. In addition, the company provides contract development and manufacturing services for pharmaceutical companies; and manufactures and sells specialty ingredients used in the nutraceutical, dietary supplements, and cosmeceutical products. Further, it develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceutical field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.

Latest News
No recent news

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms